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Abstract
Cellular therapies are an attractive area of regenerative medicine. For large partial 
thickness wound, keratinocytes transplant is suggested. The transplantation of cell 
graft is achieved by obtaining large amounts of cultured cells from a skin biopsy in 3 
weeks. Stem cells can be applied before that, but are also efficient in chronic wound 
closure. Alternative treatment methods are transplants of allogeneic, biostatic skin and 
amnion. Amnion can be applied as a skin substitute on shallow facialburn wounds, 
hand burn wounds, on donor areas and granulating wounds. For medium depth or 
even deep burns, allogeneic skin is recommended. Thanks to the removing of cells from 
human allogeneic dermis, collagen scaffolding is obtained. It can be populated de novo 
by autologous skin cells. Artificial skin substitutes are especially good for hand burns 
and shallow burns. Even though scarring is a part of normal wound healing, it often 
leads to a pathological process. When scar treatment methods prove insufficient, surgi-
cal intervention becomes necessary. Surgical scar intervention involves removal of the 
pathological skin tissue fragment and replacing it with healthy skin or application of 
expanders. Improvement of the visual features can be also achieved by laser therapy.
Keywords: skin graft, skin cell graft, amniotic membrane, acellular dermal matrix, laser 
therapy, skin substitutes, scars
1. Introduction
The current trend in medicine is focused on two aspects of healing: on preventive medicine, 
preventing disease when possible and regenerative medicine, regenerating fractured cells 
[1]. The methods of treating burn wounds and chronic wounds have changed over the last 
decades [2]. Early removal of the dead necrosis and closing the wound with an autologous 
skin transplant of medium thickness (STSG) is still the basis of wound treatment [3], yet new 
methods that could provide a better esthetic effect continue to be sought after. This change 
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follows a growing consciousness of the patients and the resulting growing demand for new 
methods of wound treatment and scar healing.
2. Cellular therapies
Cellular therapies used to return the patient to the stage of skin completeness are an attrac-
tive area of translational medicine [4]. One should remember, however, that cell transplants 
(autologous keratinocytes or stem cells) were qualified as a healing product for advanced 
therapy by the Commission for Advanced Therapies of the European Medicines’ Agency 
(EMEA). Their manufacturing is thus, with all consequences, regulated by the rules of Good 
Practice [5–8]. Cultivated skin cells and products obtained by bioengineering means are used 
in treating patients with both genetic and acquired skin diseases [4]. They are especially use-
ful in the treatment of traumas of chronic surface or depth, such as burns [9]. One of the meth-
ods is the delivery of cultured cells to the bed of the wound [10] by, among others, applying 
autologous cultured cells or skin substitutes obtained by cellular bioengineering [11]. The 
transplantation of keratinocytes is achieved thanks for obtaining large amounts of cultured 
cells from a skin biopsy in 3–4 weeks [12]. One of the benefits of using stem cells is their ability 
to migrate and differentiate the endothelium [13], which promotes revascularization [14]. The 
increased optimization of microvascular activity is the result of the injection of stem cells into 
a protracted wound [13]. What is more, the application of cells affects local cellular response, 
which plays an important role in the rebuilding of skin integrity in the infected wound [15]. 
It has been proven that stem cells from adipose tissue rebuild skin layering [7]. In our clinic, 
a positive result was obtained in all the cases of injecting stem cells from adipose tissue into 
the wound bed [16] (20 patients). There is a thesis that the transplant of allogeneic cells of the 
amnion can be more effective in the treatment of chronic wounds than autologous stem cells 
from adipose tissue or bone marrow [17]. Skin epidermis transplants with amniocytes act in 
an almost physiological way, which suggests that in the stimulation of the stratification of 
keratinocytes, fibroblasts can be replaced [18]. Fibroblasts seeded over the amnion show good 
adherence and longevity [19]. This type of wound dressing is suggested for chronic wounds 
and burn wounds [19, 20]. Alternatively, seeding the keratinocytes over the allogeneic, acel-
lular amnion stimulates their proliferation. The life span of seeded cells is up to 4 weeks [20]. 
Experience shows that stem cells of the amnion shorten the time of wound healing by two-
fold. The culturing of keratinocytes was implemented in the Center in 2008. Since then, about 
200 cellular transplants have been effectuated in patients with burn wounds, mostly thermal 
wounds. About 75% of the patients where qualified for the culturing (Figure 1). The size of 
the wound was 40–79% total body surface area (TBSA) in more than half of the patients who 
were subject to a cellular transplant. According to Sood et al., the average life of patients sub-
ject to the cultured epidermal autografts (CEA) transplant is 91%, while we obtained 88%. It is 
worth remembering that when it comes to cells of the epidermis, key is the right matching of 
the patients as leading complications are dermal blisters, itchiness and the loss of the cellular 
transplant. A common and chronic after-effect is the occurrence of swollen scars [21]. One 
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solution seems to be the use of stem cells [22] which help reduce the scarring [23]. The cells 
of the epidermis help the heeling of wounds to the maximum depth of IIb. Mansilla et al. and 
Rasulov et al. suggest the use of stem cells for wounds of great depth [24, 25].
RenovaCare is now performing clinical trials of the SkinGun™, which is to distribute stem 
cells as a suspension (fog) into the wound bed. The isolation, processing and application of 
the autologous cells takes only 90 min. The inventors of the gun have obtained an award 
for the patent and assure users that the vitality of the obtained stem cells is up to 97.3% 
[26]. HARVEST TERUMOBCT used the The Harvest® AdiPrep® system, allowing to obtain 
a suspension of cells (containing mesenchymal stem cells) in 4 minutes. The singular plat-
form produced by this company allows to transform the platelet rich leukocyte concentrate 
of bone marrow and fatty tissue into stem cells with the concentration of 160,000/ml and 
vitality from 78 to 95% [27]. Cytori Therapeutics, Inc. also proposes a device for autologous 
cell therapy using fractions of cells sourced from fatty tissue (ADRCs). Adipose tissue is a 
good source of stem cells, but the sine qua non condition for the use of The Celution® System 
is the minimal amount of fatty tissue of 200 g. In our experience, the whole sourcing and 
transformation process takes about 2.5 h even though Fraser and associates cites 1.5 h [28], 
the equivalent of the transformation of the framework in our device. Our Center uses this 
system as liposuction is a noninvasive procedure while the amount of sourced stem cells and 
regenerative cells does not require a long cell culturing process. The vitality of cells obtained 
using the The Celution® System is 93% and is higher than that coming from the PNC’s Multi 
Station (a manual device), the CHA Biotech Cha-Station and the Medi-Khan’s Lipokit from 
MaxStem [29]. In our Center, this system is used for the treatment of chronic wounds as 
it allows for the operation to be performed on the day of admission which shortens the 
Figure 1. The right choice of the research field for the sourcing of autologous skin for culturing (1) is often problematic 
due to the limited amount of available research fields (2). The culturing of the epidermis for the transplant (3) and wound 
before the transplant (4). The source material for the isolation of stem cells (5), stem cell culture (6), the transplant (7) 
and the final result (8).
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patient’s hospitalization time and allows for the assurance of enough hospital beds to meet 
the needs of the other burn patients. Subjects included for this procedure contained patients 
who did not properly responded to CEA therapy and those with non-healing wounds. The 
procedure of applying ADRC cells sourced from The Celution® System was performed since 
2011 in 20 patients (aged 18–80 years old). Good clinic results (final wounds closure) were 
obtained, which is a huge success preceded by the many months of non-responsive to heal-
ing wounds before the procedure (Figure 2).
The biggest limitation of the commercially available systems of sourcing stem cells for trans-
plants is the amount of obtained cells, which is why burn patients qualify for stem cells 
cultured in a Stem Cell Bank. This is most effective from the point of view of a therapeutic 
success, yet much more complicated from the legal and financial point of view. It requires the 
production of stem cells in accordance with pharmaceutical law in Clean Rooms. Our Center 
has carried out a transplant of amniotic stem cells in a hospital exclusion which requires an 
extra permission from the bioethical commission and the signing of a conscious consent from 
the recipient. A 30-year-old patient with a thermal wound of 36% IIb/III got the cells in the 
fourth day after the burn. In 12 days, the wounds healed to a very good esthetic effect. It was 
Figure 2. The isolation and application of regenerative cells from fatty tissue: liposuction (1), the sourced lipoaspirate (2), 
wound bed injection combined with a grated autologous skin cell transplant (3), the healing of the wound 7 days after 
the procedure (4), the final effect: a functioning, intact limb (5).
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said that the legal regulations prevent the procedure from being routinely used. To sum, the 
good effects of cellular engineering in the last 30 years have been achieved in field of treat-
ment of chronic wounds, such the diabetic foot and venous ulcers as well as deep wounds 
[30, 31]. It seems they will become a canonical medical practice. The only question is the right 
choice of therapy methods for the given patient.
3. The allogeneic amnion
The preparation which is an optimal alternative for traditional treatment methods is a trans-
plant of allogeneic, biostatic amniotic tissue [19]. Amniotic tissue is a thin, half-permeable 
tissue which constitutes the most inner layer of the amnion and is obtained from seronegative 
donors during pre-planned Cesarean sections. Histologically, the amnion is a five-layer mem-
brane from 0.02 to 0.5 mm thick. Amniotic membrane transplants are undertaken in sterile 
environments and undergo a final radiative sterilization [20]. The clinical reason for amniotic 
membrane transplants stems from its natural properties, such as
• it being non-immunogenic, mainly an effect of the expression of HLA-G genes in the pla-
centa and amniotic liquid, which are responsible for the immune response during the preg-
nancy [34],
• reducing the risk of infection; it has been proven that the aqueous solution of the amniotic 
membrane promotes the apoptosis of monocells, such as lymphocytes and macrophages. 
[35]. This effect is proven by the latest research of Alikarami et al., which have proven the 
limiting effect of mesoenchymal amniotic liquid cells on the proliferation of mitogenically 
active T lymphocytes in the in vitro coculturing of T lymphocytes [36],
• its anti-inflammatory properties; the antibacterial effect observed during the application 
of the amniotic membrane in the process of wound healing is a common and documented 
phenomenon. The antibacterial effect is thought to be due to the presence of lysozyme and 
progesterone in the amniotic liquid as well as the very exact link between the dressing and 
the wound. Lysozyme is a protein with the properties of a hydrolytic enzyme which breaks 
down the peptidoglycan present in the cell wall of the bacteria. Progesterone is bacterio-
static against many Gram (+) bacteria [32, 33, 37, 38],
• as well as modulating the stroma of the wound; the stromal matrix amnion is rich in extra-
cellular matrix content, such as hyaluronic acid from the embryon, glicosaminoglicanos, 
various types of collagen and growth factors which promote and modulate the regenera-
tive processes occurring in the wound [39],
• stimulating proliferation processes; due to the rich ECM content. The amniotic membrane 
of the amnion included laminin, fibronectin, collagen IV, V and VII, as well as growth fac-
tors such as TGF, which greatly facilitates the adhesion and anchoring of the endothelial 
cells in the stroma and their proliferation [39, 40],
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• minimizing pain; the painkiller effect is due to the very close link between the amniotic 
membrane and the wound, thanks to which the exposed, irritated nerve endings are pro-
tected [19, 33].
The clinical scope of the use of the amniotic membrane may include its application as a 
skin substitute on facial burn wounds, hand burn wounds, on donor areas and granulating 
wounds. An alternative is the STSG wound dressing of high gradation. Amniotic membrane 
transplants are useful also in the treatment of autoimmune diseases, for example, the Lyell’s 
disease [18, 19]. The amniotic membrane can be used together with biological wound dress-
ings, such as allogeneic skin [12, 20]. Properly aseptically prepared biovital transplants such 
as allogeneic transplants of the amniotic membrane are of high interest today. Good results of 
intravital transplants of the amniotic membrane in the treatment of wounds can result from 
the physiological functions of secretion of the amnion cells [41].
The Dr Stanisław Sakiel Centre for Burn Treatment in Siemianowice Śląskie, we began the 
undertaking of biostatic transplants of the amniotic membrane in 2011. The transplants are 
produced in the Clean Rooms of the Cell Bank in accordance with the Good Manufacturing 
Practice (GMP) (Figure 3). From August 2011 to March 2017, 245,229 cm2 transplant cells have 
been produced. 513 patients have been served by a total of 235,317 cm2, including 9 patients 
with the Lyell’s Syndrome (Figure 4).
The obtained evidence and clinical observation suggest a conclusion that the amniotic mem-
brane is an optimal skin substitute in the treatment of shallow burn wounds, specifically facial 
burn wounds.
Figure 4. The clinical effect of the therapy of Lyell’s effect in days: 0, 5 and 15.
Figure 3. Select stages of production of allogeneic, biostatic transplants of human amnion: (1) the amniotic membrane 
in a transportation container; (2) rinsing; (3) cutting uneven fragments, measuring the surface; (4) a packaged transplant 
before sterilization by radiation.
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4. The allogeneic skin
Allogeneic skin, obtained mainly from dead, and rarely from living donors, has the properties 
of an ideal wound dressing: it protects the wound, stimulates healing and reduces pain. This 
is why is so successful in treating skin diseases such as Stevens-Johnson’s disease and Lyell’s 
disease [22]. Allogeneic skin is also used for the treatment of topical burn wounds and deep 
wounds alike, especially when there is not enough of the patient’s skin available to dress their 
wound [43, 44]. One of its biggest advantages is the ease of gathering it, the possibility of gath-
ering enough for a huge grafting surface, its low toxicity, the ease of keeping it and the rela-
tive ease of application [45]. In the case of both widespread and deep wounds, allogeneic skin 
used to dress a surgically cleaned wound prevents the skin from loosing water, electrolytes 
and proteins, while at the same time preventing the dehydration of other cells. Moreover, by 
being a barrier against environmental stimuli, it reduces the proliferation of microorganisms 
[46]. Thanks to a lowered heat loss experienced by the wound, the hypermetabolic response of 
the skin to the burn wound diminishes. In wounds suffered by all the layers of skin and thus 
lacking regenerative potential, an allogeneic skin transplant stimulates the granulation pro-
cess and wound epithelization, thus creating a stroma for further surgical intervention [47]. 
The allogeneic skin is also a good biological dressing, which is effective in the treatment of 
burn wounds of medium depth, covering the epidermis and the dermis. The allogen initiates 
the growth of blood vessels in the wound bed and stimulates revascularization. While closely 
adhering to the stroma, it minimizes the level of pain and reduces the amount of necessary 
dressing changes, allowing for the process of the recreating of the epidermis to continue 
while the allogen disassociates itself from it without violating the emerging epidermis [48]. 
In certain cases, allogeneic skin serves as a dressing of wounds previously covered by mesh 
transplants of autologous skin, allowing to minimize metabolic stress and prevent infections 
within the wound and creating scaffolding for in vitro cultured keratinocytes [42]. In the 
Center of Wound Treatment in Siemianowice Slaskie, allogeneic skin is the standard operat-
ing procedure for patients with severe wounds, allowing for the temporary dressing and 
protection of wounds [49]. Moreover, it is also used when the exact depth of the wound can-
not be determined while a risk of the wound deepening and the loss of the entire autologous 
transplant exists [50]. In our clinic, allogeneic skin is used also for the treatment of wounds 
of medium depth as a dressing meant for the stimulation of granulation tissue and the final 
closing of the wound thanks to its initiation of the epithelization process [51]. Allogeneic skin 
was first included in preparations in 2009 while the first transplant was executed in early 2010. 
At first, it was sourced from multiple organs. Due to clinical demand, from 2014 skin from 
Departments of Forensic Medicine is being used. Skin sourced in the latter way carries the risk 
of infected material increased by 58%, with the most common pathogen being Klebsiella pneu-
moniae [52]. In 2016, allogeneic skin was transplanted 235 times. The skin was sourced from 
about 50 donors. Until the end of 2016, the total amount of donors grew to 163. Allogeneic 
skin transplants sourced from dead people fulfilling the criteria of donors in accordance with 
the Bill of Law from July 1, 2005 on the sourcing, storage and transplantation of cells, tissue 
and organs is being prepared in the Cell Bank and in vitro Cell Culture Center in the Center 
for Burn Treatment. The transplants are then sterilized by radiation to eliminate dangerous 
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pathogens, microbiologically tested and checked for viruses to conclude the sterilization pro-
cess. If the results of the tests are negative, skin substitutes are stored in −80°C until applica-
tion. The next stage, performed under anesthetics at the Surgical Ward, the burn wounds are 
surgically cleaned from dead tissue. Then the allogeneic skin is grated and applied to the 
wound. After the application of the transplant, the wound is dressed in an external wound 
dressing. The next stages of the dressing of burn wounds by allogeneic skin transplants are 
pictured in Figure 5.
Patients of our Center with IIB wounds and some patients with IIB/III wounds had the alloge-
neic skin transplant lead to a definitive closing of the wound, despite a previous nephrectomy, 
resulted in the stimulation of the growth of cells in the wound bed and the revascularization 
of the wound, as well the initiating of the epithelization process (Figure 6). This eliminated 
the need for an own skin transplant to be performed on the patient [49, 51]. Similar results 
have been observed by Oliver and associates, who have proven that allogeneic skin modu-
lates the proliferation process, as well as differentiation of granulation tissue [53].
Other patients with deep skin burn wounds had allogeneic skin used as a dressing prevent-
ing the loss of water, microelements and proteins, as well protecting them from bacteria and 
viruses. The dressing was a source of cytokines and growth factors stimulating chemotaxation 
and the proliferation of cells, stimulated the grantulation of tissue and prepared the stroma 
for a surgical intervention and provided grounds for the definitive closing of the wound 
thanks to an autologous skin transplant. Moreover, allogeneic skin is used in the Center when 
it is impossible to assess the depth of the wound and when there is a clear risk that it can 
deepen and the transplant can be rejected, as well as when the patient has a limited amount 
of source beds for own skin transplants [50]. Allogeneic skin is also applied on wounds com-
ing from as escharotomy. To conclude, allogeneic skin is a good alternative to autologous 
skin transplants. An allogeneic skin transplant results in the complete healing of the wound, 
Figure 5. The allogeneic, biostatic transplant (1 and 2), the grating of allogeneic skin (3), a IIB burn wound cleaned from 
dead tissue (4), the application of an allogeneic skin transplant (5) and the application of an external wound dressing (6).
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 eliminating the necessity for own skin sourcing for the transplant, which could result in fur-
ther complications, pain and scarring. It is worth noting, however, than allogeneic skin can 
only be a temporary wound dressing, allowing for and facilitating the autologous skin trans-
plant, which remains one of the best methods of closing a burn wound [54].
5. Acellular collagen human skin matrix (Acellular dermal matrix, ADM)
In order to improve the properties and the longevity of the transplants, tissue engineering 
methods such as cell removal are used. The reason for the removal of cells from tissues/organs 
is the obtaining of a non-immunogeneic transplant, which could be populated in vivo by the 
patients’ own cells after the transplantation is completed [21]. A transplant devoid of cells is 
thus composed of the elements of an extracellular matrix, the ECM. The influence of the ECM 
on the mitogenesis and chemotaxis of cells and their targeted differentiation has been proven. 
It has also been proven that the ECM induces the creation and promotes the constructive 
remodeling of the host’s tissue. Correctly used materials can modulate certain stages of heal-
ing by helping and inducing the transition from the inflammatory period to the constructive 
restructuring of the fractured cells. Effects observed during the interaction between the used 
biomaterial and the body of the recipient are complex and include immune system reactions, 
the proliferation of stem cells and their differentiation [55]. Moreover, ECM has many elements 
that are produced and populated by its colonizing cells. Between the extracellular matrix and 
the cells, a dynamic mutual relationship occurs. It affects their microenvironment and the pro-
liferation and differentiation of cells. The described phenomena occur in natural body homeo-
stasis, but are key for the healing of the wound [56]. The ECM cells regulated the biosynthesis 
of collagen and the processed of production of other elements of the extracellular synthesis. 
The role of these cells is the regulation of all the processes of biosynthesis, transformation and 
degradation of connective tissue [57]. Cellular residue, however, coming from the aftermath 
Figure 6. The patient on the day of admission to the Center (1), on the third day after the allogeneic skin transplant (2), 
on the 16th day from the hospital admission (the day of leaving the Center) (3).
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of the process of restructuring of allogeneic cells can provoke an unwanted immune response, 
which can in turn destroy the transplant [58, 59]. As the autoimmunological response is 
mostly targeted against proteins and fatty cells of the cellular tissue, the removal of cells 
from the tissue is a promising method that may lead to the sustaining of the induction of the 
immune response in the patient’s body after the transplant [58, 60, 61]. The removal of cellular 
components should minimize the immune induced inflammation, which may weaken the bio-
degradation of the transplanted bioprosthesis. It is worth noting that the process of removing 
cells from tissue does not completely eliminate the immune response [62]. The process of 
eliminating cells from tissue/organs is chemical, enzymatic and mechanical in the genesis of 
how the cellular material is eliminated. In order to the removal of cells from human allogeneic 
skin, a collagen scaffolding is obtained, which can be de novo peopled by autologous skin 
cells and transplanted into the are that lacks [33]. The process of removing cells from tissues/
organs is comprised of chemical, enzymatic and mechanical techniques of elimination of cel-
lular matter. Thanks to the removing of cells from human allogeneic dermis, collagen scaf-
folding is obtained. It can be de novo populated by autologous skin cells and transplanted into 
the skin damage area. The method of treating burn wounds based on the use of human allo-
geneic, acellular extracellular matrix of the dermis (acellular dermal matrix, ADM) as a matrix 
for in vitro cultivated autologous fibroblasts and keratinocytes can be an effective method in 
the treatment of burn wounds [22]. The clinical need of using this method arises in patients 
with deep burn wounds of at least 50% TBSA and when the sites from which the skin was 
obtained for autologous skin grafting heal badly [12, 15]. In the Dr Stanisław Sakiela Burn 
Centre in Siemianowice Śląskie, the application of acellular human skin matrix (ADM) began 
in 2015. Until March 2017, an ADM transplant was executed on six patients. Those qualified 
for the procedure had deep burn wounds which healed badly. Based on the obtained results 
and clinical observation, we concluded that the use of ADM with in vitro cultured skin cells 
can be an optimal treatment method for burn wounds. To obtain a definitive scientific result, 
however, the number of the analyzed cases has to be increased [63–66].
6. Skin substitutes
The use of skin substitutes is an alternative to auto-and allogeneic transplants in the treat-
ment of wounds of various provenance, including burn wounds and chronic wounds. Skin 
substitutes have to meet certain criteria to fulfill their function as actual “substitutes”. They 
should not be immunogenic for the patient. They should modulate the proteolytic activity 
of the wound. The main role of synthetic skin substitutes is the provision of a bioresorptive 
scaffolding which facilitates cellular migration and deposition of the extracellular matrix [23]. 
This scaffolding should also stimulate angiogenesis and promote the migration of skin cells 
(fibroblasts), stimulate the synthesis of granulation and absorb and neutralize free radicals. 
The ideal skin substitutes should be commonly available and able to recreate various func-
tions and layers of the skin in a short time. Skin substitutes have to undergo vascularization 
quickly and integrate fast into the wound bed of the patient. The majority of the currently 
available materials are based on scaffoldings of cattle collagen (e.g. Integra) or beef  collagen as 
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well as allogeneic keratinocytes and fibroblasts (Apligraf) [24]. Other substitutes are human-
based skin equivalents, such as Apligraf®, Dermagraft® or TheraSkin® [25]. Other substi-
tutes are acellular, natural biopolymer scaffoldings, such as Kolagen, Oasis®, GraftJacket®, 
DermACELL®, EpiFix®, Integra™, Promogran™, alginians and chitozans.
In the case of burn wounds, the first stage of treatment is the removal of dead tissue and a 
temporary wound closing, which at best may be definitive [30, 67]. A necrotomy procedure, 
removing the source of the infection, which is dead cells, affects the humoral reaction of the 
system and the amount of endotoxins in the patient’s blood [30, 68]. There are many sub-
stitutes that can be used for wound dressing. In our Center, we use human biostatic trans-
plants skin, allogeneic amnion, cellular transplants (of keratinocytes and fibroblasts) as well 
as commercially available synthetic substitutes. Based on years of clinical research, we devel-
oped recommendations for the use of particular skin substitutes. We have experience in the 
use of three commercially available skin substitutes: Suprathel, Oasis and Biobrane. Shallow 
wounds, usually of the IIA type, benefit from Suprathel as an epidermis substitute. The deci-
sion on using a certain skin substitute is made every time by the lead doctor for every given 
patient. The final decision on the use of a synthetic substitute instead of an own skin trans-
plant of an allogeneic transplant is often made in the operations room after the cleansing of 
the wound.
Suprathel is a resorbed epidermis substitute characterized by a high permeability of oxygen 
and steam and matching the physiological qualities of human skin. The pH of the dressing is 
initially 5.5 and a later 4.0 (in in vitro conditions). The risk of infection when using this dress-
ing is minimal. Suprathel is made of lakto-kapromer, its main ingredient being polylactic acid. 
It is fully synthetic and does not include collagen, so the biological risk is fully eliminated 
here. The time of hydraulic degradation of the dressing is 4 weeks.
We use Suprathel in our Center since 2011. That year, we used this substitute on burn wounds 
of 5 × 5 cm area in five patients and on the 9 × 10 cm in five patients. Starting in 2012 and upon 
the observation of the first clinically positive effects of the dressing, Suprathel became more 
and more popular in our Center. Below is a diagram detailing the use of Suprathel in 18 × 
23 cm increments in 2012–2016 (Figure 7).
During these years, Suprathel was mainly used in the Surgical Ward in artificial skin trans-
plants. However, it was used twice in the Anesthesiology and Intensive Therapy Ward 
(Figure 8).
Deeper, IIB wounds are treated by Biobrane and Oasis in our Center. Biobrane is a dressing 
made of ultrathin, half-permeable membrane kept together by an elastic nylon band. It is 
made of a nontoxin mix of highly purified peptides made from collagen isolated from por-
cine skin and kept together by a nylon/silicone membrane. This structure ensures high elas-
ticity and a fitting of the dressing to the wound. This substitute is highly adjoined and very 
hydrophilic and biocompatible. It is a 3D structure, containing a natural extracellular matrix 
facilitating the migration of cells, the filling of the wound and the stimulation of healing [45, 
69]. In our Center, Biobrane was used as the first commercially available skin substitute. In 
2008–2012, it was used in the burn wound ward: once in the 13 × 13 cm size and nine times 
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in the 13 × 38 cm size. In the first stage, Biobrane was used in the cosmetic treatment of burn 
and chronic wounds and used with anesthetics. Later on, Biobrane was also used during 
surgery. Biobrane is a mutlipurpose biosynthetic dressing [70]. It is a relatively inexpensive, 
easy to store and reliable dressing when used according to recommendations [71]. Despite 
its several pros, Lal et al. suggest that it should only be used on wound not deeper than 25% 
Figure 7. The amount of Suprathel used in 2012–2016.
Figure 8. The wound (1) before the application of Suprathel (2) after the application of a substitute (3) upon heeling with 
Suprathel.
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TBSA to exclude the risk of infection [72]. Hubik et al. confirm that Biobrane carries a 37.8% 
risk infection [73]. Our experience confirms this data: in rare cases, an infection of the substi-
tute occurred after it was transplanted on the cleansed burn wounds. Oasis is another skin 
substitute good for deeper wounds and chronic, seeding wound of the IIB type. This substi-
tute is a natural matrix (Healthpoint) made of submucosal porcine lower intestine containing 
ECM (>90% collagen). It is thin (ca. 0.15 mm), half transparent and contains mainly type I 
collagen. The porcine component has a porous structure with pores of 20–30 μm that allow 
for the diffusion of oxygen and facilitates the survival of cells [74]. It maintains the biological 
activity of other skin elements that allow for binding of the cell growth factor and enzymes 
degrading the matrix, which allows an increased permeability of the cells and their access-
ing the fractured tissue. The matrix is the place of settling of glycosaminoglycans, proteo-
glycans, fibronectin and other growth factors, which gives is responsible for the substantial 
biological activity of this substitute [75–77]. This way, it gives not only the structural matrix, 
but provides growth factors as well, stimulating the angiogenesis and cellular migration, 
regulating the proteolytic activity and halting the extracellular matrix metalloproteinase: 
MMP-1, MMP-2 and MMP-9, affecting the migration of keratinocytes [78]. In our Center, 
we demarcated the matrix and applied the Oasis dressing during one procedure in the case 
of six patients between 2009 and 2015. In the case of each of these substitutes, the proper 
preparation of the wound bed is key. The wound has to be chemically or surgically cleansed. 
A very good method is VersaJet—a water knife removing dead cells. A wound cleansed of 
dead tissue has to be dressed with the substitute as recommended by the producer in terms 
of direction. The protection of the substitute is achieved by covering it with gauze soaked 
in vaseline (e.g. Jelonet), which is further covered by gauze dressings ready to injected with 
water and covered with bandage. The change of the dressing should happen no earlier than 
in the second day after the surgical procedure. Due to Suprathel being biodegradable, there 
is no need to remove it after the changing of the dressing unless and infection occurs. In 
this case, the infected substitute has to be removed immediately, cleanse the wound again 
and introduce antibacterial or antifungal procedures. To conclude, the use of commercially 
available skin substitutes in the treatment of burn and chronic wounds is a common practice 
in most Centers dealing with these kinds of wounds. Due to the high differentiation of the 
available products, each Center should develop its own procedure governing their good use. 
The procedures we described are ready recommendations for the use of commercially avail-
able skin substitutes which can be implemented in the treatment of patients with burn and 
chronic wounds. Due to their structure, epidermis substitutes are good for shallow wounds 
no deeper than IIA. Synthetic epidermis substitutes and natural skin substitutes may be 
equivalent to free skin transplants of medium depth and can be used on cleansed wounds no 
deeper than IIB [79, 80].
7. Scars treatment
Another group of skin substitutes is made of acellular synthetic polymer matrix. While they are 
available on the market of skin substitutes, they have various limitations, such as limiting vas-
cularization, heightening scarring, low mechanical resistance and the danger of being rejected 
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by the patients’ immunological system. Synthetic skin substitutes often do not  vascularize, 
which leads to the necrosis of cells and the final separation of the transplant from the wound 
[26]. An important limitation for the use of commercially available skin substitutes is the cre-
ation of scars, which lead to functional, mechanical and esthetic problems [27]. Even though 
scarring is a part of normal wound healing, it often leads to a pathological process. When the 
connective tissue fills the fractured skin part, it does not lead to the creation of a regular skin 
tone as the fibrous tissue lacks natural skin pigment. The connective tissue lacks hair follicles 
as well, which is why scars in hairy places can pose serious esthetic challenges. The uncovering 
and mechanisms of scarring would allow to determine the exact prophylaxis and therapeutic 
measures to undertake. A series of methods for the treatment of scars exist, yet neither one of 
them is fully effective. Since the use of one single method provokes a rapid relapse of the ill-
ness, a combined therapeutic approach is usually administered, allowing for a good cosmetic 
effect [28]. The combined therapeutic approach employing cryotherapy alone or combined 
with the use of steroids is one of the leading ways of scar treatment. Another method of 
improvement of the visual features of wounds is laser therapy. Its effectiveness is judged in 
various ways because of the type of wounds that can undertake this therapy. Its effects are usu-
ally augmented by corticosteroids. Another method, pressotherapy is based on treating scars 
by administering controlled pressure. Different compression models, compression clothes and 
clips’ are used to this effect [29]. When scar treatment methods prove insufficient, surgical 
intervention becomes necessary. It involves the removal of the pathological skin tissue frag-
ment and replacing it with new and healthy skin, usually sourced from other parts of the 
patients’ body. Another surgical method for burn removal is the application of tissue stretchers 
(expanders). The use methods of burn treatment should result in the improvement of esthetic 
qualities of the patient, which further affect their self-confidence and quality of life [81]. More 
importantly, however, the aim of the therapy is to minimize clinical symptoms by minimizing 
or eliminating pain and burning and obtaining the full functionality of the joints affected by 
scarring. Wound treatment is a process of many stages, including various therapeutic methods 
depending on the level of maturity of the wound. The surgical procedure itself must be planned 
in a way that has in mind the caring for the scars. The removal of the necrosis should lead to 
retention of a reticular layer of the dermis, which allows for the faster healing of a wound 
thanks to less closely adhering scar. The use of VersaJet in the early resection of the necrosis 
positively impacts the look of the cleansed wounds. Depending on the type of transplant, the 
look of the wound at various stages of healing can be very different. The best esthetic effects are 
obtained by closing the wound with an autologous transplant of medium depth. A good cos-
metic effect is also obtained by an in vitro transplant of autologous keratinocytes and fibroblasts 
in the grafted transplant of medium density. We have observed a good cosmetic effect of com-
mercially available skin substitutes (Oasis, Biobrane). Besides prophylaxis, the treatment of 
wounds should lead to the creation of a soft, regular, non-discolorated surface. During the 
treatment, the creation of pathological wounds has to be avoided thanks to the provision of 
quick wound healing, the prevention of infections or and scar contractures (thanks to railing 
and rehab). At the first stage, a mild finger massage of the wound and the use of silicone gels 
and ointments are recommended. The silicone prevents the loss of water, the drying and chap-
ping of the wound and alleviates the burning sensation. A layer of ointment or gel protects the 
wound from external dangers and mechanical damage, as well as creating slight pressure, 
which is why a finger massage is recommended before its application. The use of silicone band 
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aids is recommended at the night-time, as they delicately pressurize the wound, preventing its 
drying. The most common silicone gels are Dermatix, Veraderm, Medigel and Cicacare and 
band aids are used [82]. Constant wound pressuring is obtained by pressotherapy using flexi-
ble fabrics. The effectiveness of the therapy depends on the choice of the correct pressure: too 
little may not be effective, too much may lead to side effects such as chafes, abrasions, macera-
tion of the skin, sores or blisters. In the treatment of severe burn wounds, pressure clothing is 
used, employing slight pressure, classified by the European Standardization Commission as 
class I (18–21 mmHg). These clothes should be used for 6–24 months from the end of the wound 
healing until cosmetic effects such as the flattening, whitening and reduction of the size of the 
scar are achieved. The effectiveness of pressure clothing depends on their size, which is why 
they have to be fitted exactly and exchanged in the case of a change in body size (specifically in 
children) [82]. Scars can be treated by various methods. In our Center, we most commonly 
employ surgical treatment and laser therapy. Wound correction may comprise of their cutting 
out and sewing together, thus changing their direction and alleviating skin pressure. The cut-
ting of skin must be undertaken with respect to the Langer lines. Surgical methods of wound 
healing used in our Center are topical, such as the “Z” method, based on making a cut of the 
“Z” shape. The middle part of this cut is perpendicular to the long axis of the closed wound 
and situated at least 3 cm from the wounds’ brim. The angles between this section and the rest 
should be 30–90°. During the coming together of the wound brims, the resulting triangular 
areas change places and the “Z” shape changes from perpendicular to parallel to the long axis 
of the wound. This method was used six times a year. Another method of surgical wound treat-
ment is using neighboring skin. It is thicker and stronger than the transplanted skin, which is 
why it can be used on areas devoid of veins. These methods are used in the treatment of con-
tracted wound of the limbs, corpus and eyelids [83–85]. Laser therapy may, depending on the 
type of the laser, be used in the treatment of wounds at various stages of their maturity. At the 
level of wound healing, biostimulating lasers can be used. Biostimulation used low energy 
lasers (stimulants). These lasers emit rays up to 5 mW [83], and the wavelengths emitted by the 
lasers used in the biostimulation fall in the middle of the electromagnetic spectrum [84]. 
Biostimulation uses mainly lasers such as the He-Ne laser helium-neon and the arsen-gala 
semiconductor diode. The biostimulation process itself is effective in providing a predeter-
mined amount of energy, expressed in Joules (J) to an appropriate depth. The degree of absorp-
tion and the penetration of the radiation are dependent on both the structure of the irradiated 
tissue, its blood flow, pH, water content, pigment, melanin and hemoglobin, as well as the 
wavelength, the color of light, its strength and the duration of treatment [84]. Upon the forma-
tion of the scar, our Center uses CO
2
 laser ablation. The CO
2
 laser emits radiation at a wave-
length of 10,600 nm, which is continuous at the power of 30–100 W [83]. The radiation emitted 
by a CO
2
 laser is invisible to the eye and absorbed by the intra- and extracellular fluid [85]. The 
absorption of the laser light is not selective and results in tissue damage to a depth of 0.6 mm. 
This causes thrombotic necrosis reaching 0.4–0.5 mm deep. A reticular layer of the skin is then 
formed due to thermal damage to the surrounding area of evaporation, which can sadly cause 
significant scarring at the site around the lesion [85]. The beneficial effect of the CO
2
 laser radia-
tion on tissue involves the evaporation of the affected tissue. This impact can, however, be 
complicated by adverse changes in the skin [85, 86]. This laser is used in the treatment of scars 
due to the very good absorption of water and shallow penetration of the tissue. Since water is 
the major component of tissues, it allows the beam of the laser to cut both soft tissue and even 
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bone. This is why the laser is use in other medical fields such as gynecology, dermatology, 
ENT, where surgical intervention is necessary [83, 87]. CO
2
 laser ablation procedures must be 
repeated three to five times to make their effects lasting and sufficient. Long intervals between 
treatments must be kept, allowing from 4 to 5 weeks to regenerate the patient’s tissue. It is 
important to maintain sufficient extent of treatment, as during each session of laser therapy, it 
is only performed in about 15–25% of the scars (Figure 9). These treatments are performed in 
our Center’s department of cosmetic surgery on an average of 96 times a year, with 93 times 
being laser therapy aiding in condition of scarring and fibrosis of the skin [88].
To conclude, the process of healing scars comes in stages and begins with the resection of the 
necrosis, which has to be carried out in such a way as to leave a layer of reticularis dermis and 
to perform the cuts Langer lines. This is the first stage of prophylaxis to prevent the forma-
tion of ugly scars. The type of transplant has a decisive influence on the appearance of scars, 
with the most cosmetically sound scars created by an medium depth solid transplant or an 
autologous keratinocytes and fibroblasts transplant in the scaffolding of a reticulated trans-
plant. The very process of scar treatment should begin as soon as possible. Already the wound 
healing process can be aided by biostimulating lasers. The prophylaxis of scars includes the 
prevention of wound infection and contracted scars. Upon healing of the wound, the first step 
of scar treatment is a finger massage and the use of silicone gels and ointments, then pressure 
therapy using pressure clothing. Upon the forming a pathological scars, surgical methods 
such as the “Z” cut method and neighboring skin method, as well as laser therapy using the 
ablative CO
2
 laser.
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